Article Text

PDF
Risk of cancer was still increased over 2 years after stopping hormone therapy

Statistics from Altmetric.com

G Heiss

Dr G Heiss, University of North Carolina School of Public Health, Chapel Hill, NC, USA; gerardo_heiss@unc.edu

STUDY DESIGN

Design:

randomised placebo-controlled trial (Women’s Health Initiative [WHI] trial).

Allocation concealment:

{concealed}*.†

Blinding:

blinded (participants, clinicians, {data collectors, outcome assessors, and safety committee}*).†

STUDY QUESTION

Setting:

40 clinical centres in the USA.

Patients:

16 608 postmenopausal women 50–79 years of age with an intact uterus. 15 730 women (mean age 63 y) were included in the postintervention phase.

Intervention:

Conjugated equine oestrogen (CEO), 0.625 mg/day, plus medroxyprogesterone acetate (MPA), 2.5 mg/day (n = 8052), or placebo (n = 7678).

Outcomes:

included all-cause mortality; cardiovascular (CV) events (coronary heart disease [CHD], revascularisation, stroke, and thromboembolism); cancer (invasive breast, endometrial, colorectal, and all); fractures; …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.